{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:55:08Z","timestamp":1768697708825,"version":"3.49.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma characterized by significant genomic instability. Patients with MCL who progress on targeted therapies have a short survival; thus, novel therapeutic strategies are urgently needed. Overexpression of transducin \u03b2-like protein 1 X-linked (TBL1X) has been documented in several types of cancer and associated with poor prognosis. TBL1X is a critical regulator of multiple oncogenic networks; however, its function in MCL has not been explored. Our data show that, unlike normal B cells, MCL cells express abundant levels of TBL1X and that genetic knockdown of TBL1X and treatment with tegavivint (Iterion), a first-in-class small molecule targeting TBL1X, promote MCL cell death in\u00a0vitro and in\u00a0vivo. Moreover, TBL1X controls the stability of key MCL oncogenic drivers, cyclin D1 and RAD51; and targeting TBL1X results in significant DNA damage, cell cycle arrest, and ultimately cell death. Combining tegavivint with poly(adenosine 5\u2032-diphosphate-ribose) polymerase-1\/2 inhibitor talazoparib results in synergistic MCL cell death in\u00a0vitro, and in\u00a0vivo this combination significantly prolongs the survival of a patient-derived MCL xenograft. Together, our results define the role of TBL1X in maintaining genomic stability in MCL and establish targeting TBL1X as a novel therapeutic strategy for patients with this incurable disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015769","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T20:05:48Z","timestamp":1740600348000},"page":"2006-2018","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the DNA damage response through TBL1X in mantle cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-3454","authenticated-orcid":false,"given":"Betsy","family":"Pray","sequence":"first","affiliation":[{"name":"1Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Leon","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4390-9205","authenticated-orcid":false,"given":"Brian","family":"Barta","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirsha","family":"Koirala","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liudmyla","family":"Tsyba","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Hinterschied","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessika","family":"Carvajal-Moreno","sequence":"additional","affiliation":[{"name":"3Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Hout","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-6085","authenticated-orcid":false,"given":"Shamama","family":"Nishat","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udita","family":"Jindal","sequence":"additional","affiliation":[{"name":"4Academy of Scientific and Innovative Research, Ghaziabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Jain","sequence":"additional","affiliation":[{"name":"5Division of Cancer Biology, Council of Scientific and Industrial Research-Central Drug Research Institute, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-9566","authenticated-orcid":false,"given":"Satishkumar","family":"Singh","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-5427","authenticated-orcid":false,"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1521","authenticated-orcid":false,"given":"Wing Keung","family":"Chan","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Hanel","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5414-573X","authenticated-orcid":false,"given":"Jack","family":"Yalowich","sequence":"additional","affiliation":[{"name":"3Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-4853","authenticated-orcid":false,"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"1","key":"2025042211214097700_bib1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"2025042211214097700_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canep.2018.12.002","article-title":"Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: findings from Texas and national SEER areas","volume":"58","author":"Fu","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"12","key":"2025042211214097700_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"2025042211214097700_bib4","doi-asserted-by":"crossref","first-page":"20406207221080738","DOI":"10.1177\/20406207221080738","article-title":"Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)","volume":"13","author":"Tbakhi","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"2025042211214097700_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-017-0598-1","article-title":"Role of SOX11 and genetic events cooperating with cyclin D1 in mantle cell lymphoma","volume":"19","author":"Bea","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2025042211214097700_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.semcancer.2011.09.007","article-title":"The complex landscape of genetic alterations in mantle cell lymphoma","volume":"21","author":"Royo","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"26","key":"2025042211214097700_bib7","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fernandez","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2025042211214097700_bib8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1080\/10428194.2016.1248965","article-title":"The molecular pathogenesis of mantle cell lymphoma","volume":"58","author":"Vogt","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025042211214097700_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(00)00010-6","article-title":"Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage","volume":"102","author":"Agami","year":"2000","journal-title":"Cell"},{"issue":"8","key":"2025042211214097700_bib10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2025042211214097700_bib11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","article-title":"Cyclin D1, cancer progression, and opportunities in cancer treatment","volume":"94","author":"Qie","year":"2016","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"23","key":"2025042211214097700_bib12","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1128\/MCB.01085-08","article-title":"Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability","volume":"28","author":"Pontano","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"7247","key":"2025042211214097700_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nature08011","article-title":"F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage","volume":"459","author":"Santra","year":"2009","journal-title":"Nature"},{"issue":"6","key":"2025042211214097700_bib20","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1073\/pnas.050400997","article-title":"Mantle cell lymphoma is characterized by inactivation of the ATM gene","volume":"97","author":"Schaffner","year":"2000","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"491","key":"2025042211214097700_bib21","first-page":"eaau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci\u00a0Transl Med"},{"issue":"5","key":"2025042211214097700_bib22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2025042211214097700_bib23","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","article-title":"ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients","volume":"60","author":"Mareckova","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025042211214097700_bib24","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025042211214097700_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2025042211214097700_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MOH.0000000000000433","article-title":"DNA damage pathways and B-cell lymphomagenesis","volume":"25","author":"Knittel","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"7035","key":"2025042211214097700_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"2025042211214097700_bib28","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"1","key":"2025042211214097700_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","article-title":"Genetic interactions in cancer progression and treatment","volume":"145","author":"Ashworth","year":"2011","journal-title":"Cell"},{"issue":"7350","key":"2025042211214097700_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nature10155","article-title":"A\u00a0function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers","volume":"474","author":"Jirawatnotai","year":"2011","journal-title":"Nature"},{"issue":"21","key":"2025042211214097700_bib15","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1158\/0008-5472.CAN-10-0312","article-title":"Alternative cyclin D1 splice forms differentially regulate the DNA damage response","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res"},{"issue":"35","key":"2025042211214097700_bib16","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/sj.onc.1210319","article-title":"Functional consequences of cyclin D1\/BRCA1 interaction in breast cancer cells","volume":"26","author":"Kehn","year":"2007","journal-title":"Oncogene"},{"issue":"15","key":"2025042211214097700_bib17","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.1158\/0008-5472.CAN-05-0486","article-title":"Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity","volume":"65","author":"Wang","year":"2005","journal-title":"Cancer Res"},{"issue":"18","key":"2025042211214097700_bib18","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1128\/MCB.00049-12","article-title":"Sp1 facilitates DNA double-strand break repair through a nontranscriptional mechanism","volume":"32","author":"Beishline","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2025042211214097700_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.molcel.2011.09.002","article-title":"BRCA1 is required for postreplication repair after UV-induced DNA damage","volume":"44","author":"Pathania","year":"2011","journal-title":"Mol Cell"},{"issue":"2","key":"2025042211214097700_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41419-019-1310-1","article-title":"TBL1 is required for the mesenchymal phenotype of transformed breast cancer cells","volume":"10","author":"Rivero","year":"2019","journal-title":"Cell Death Dis"},{"issue":"8","key":"2025042211214097700_bib31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.15252\/emmm.201404837","article-title":"Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy","volume":"7","author":"Stoy","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2025042211214097700_bib32","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.7150\/ijbs.68091","article-title":"TBL1X and Flot2 form a positive feedback loop to promote metastasis in nasopharyngeal carcinoma","volume":"18","author":"Xu","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"11","key":"2025042211214097700_bib33","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3324\/haematol.2020.268235","article-title":"Transducin \u03b2-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma","volume":"106","author":"Youssef","year":"2021","journal-title":"Haematologica"},{"issue":"18","key":"2025042211214097700_bib34","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"2","key":"2025042211214097700_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","article-title":"TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate","volume":"182","author":"Venturutti","year":"2020","journal-title":"Cell"},{"issue":"7","key":"2025042211214097700_bib36","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/leu.2012.370","article-title":"Murine mantle cell lymphoma model cell line","volume":"27","author":"Smith","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2025042211214097700_bib37","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"18","key":"2025042211214097700_bib38","doi-asserted-by":"crossref","first-page":"13507","DOI":"10.1074\/jbc.M109.049411","article-title":"Direct ubiquitination of beta-catenin by Siah-1 and regulation by the exchange factor TBL1","volume":"285","author":"Dimitrova","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"2025042211214097700_bib39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1097-2765(01)00241-6","article-title":"Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein","volume":"7","author":"Liu","year":"2001","journal-title":"Mol Cell"},{"issue":"7","key":"2025042211214097700_bib40","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J\u00a0Med Chem"},{"issue":"11","key":"2025042211214097700_bib41","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/leu.2008.213","article-title":"Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2","volume":"22","author":"Klier","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2025042211214097700_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","article-title":"Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond","volume":"20","author":"Boussios","year":"2020","journal-title":"Drugs R&D"},{"issue":"10","key":"2025042211214097700_bib43","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2025042211214097700_bib44","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle Cell Lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025042211214097700_bib45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"},{"key":"2025042211214097700_bib46","doi-asserted-by":"crossref","first-page":"102090","DOI":"10.1016\/j.ctrv.2020.102090","article-title":"Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences","volume":"90","author":"Carrassa","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"2025042211214097700_bib47","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/j.1460-2075.1994.tb06488.x","article-title":"Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene","volume":"13","author":"Bodrug","year":"1994","journal-title":"EMBO J"},{"issue":"15","key":"2025042211214097700_bib48","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","article-title":"Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice","volume":"13","author":"Lovec","year":"1994","journal-title":"EMBO J"},{"issue":"17","key":"2025042211214097700_bib49","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1158\/0008-5472.CAN-11-3549","article-title":"Proteomic identification of a direct role for cyclin d1 in DNA damage repair","volume":"72","author":"Jirawatnotai","year":"2012","journal-title":"Cancer Res"},{"issue":"3","key":"2025042211214097700_bib50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/10428194.2016.1198958","article-title":"Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines","volume":"58","author":"Mohanty","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2025042211214097700_bib51","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.3390\/cancers14225697","article-title":"RAD51 is implicated in DNA damage, chemoresistance and immune dysregulation in solid tumors","volume":"14","author":"Liao","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"2025042211214097700_bib52","first-page":"2426","article-title":"Targeting RAD51 enhances chemosensitivity of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand break repair","volume":"42","author":"Yang","year":"2019","journal-title":"Oncol Rep"},{"issue":"21","key":"2025042211214097700_bib53","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.3390\/cancers13215358","article-title":"Expression levels of RAD51 inversely correlate with survival of glioblastoma patients","volume":"13","author":"Morrison","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"2025042211214097700_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bjc.6602665","article-title":"High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients","volume":"93","author":"Qiao","year":"2005","journal-title":"Br J Cancer"},{"issue":"3","key":"2025042211214097700_bib55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.yexmp.2017.05.001","article-title":"Upregulation of RAD51 expression is associated with progression of thyroid carcinoma","volume":"102","author":"Sarwar","year":"2017","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"2025042211214097700_bib56","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-013-3220-2","article-title":"Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus","volume":"21","author":"Nakanoko","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2025042211214097700_bib57","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.18632\/oncotarget.2583","article-title":"Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma","volume":"6","author":"Chila","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"2025042211214097700_bib58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"2025042211214097700_bib59","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"issue":"16","key":"2025042211214097700_bib60","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.3390\/ijms22168544","article-title":"The SCF complex is essential to maintain genome and chromosome stability","volume":"22","author":"Thompson","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2025042211214097700_bib61","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.21873\/anticanres.16677","article-title":"Exploring TBL1XR1 and NCOR1 expression in B-cell lymphoma subtypes: interaction with DNA damage repair genes","volume":"43","author":"Mansoor","year":"2023","journal-title":"Anticancer Res"},{"issue":"3","key":"2025042211214097700_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1097-2765(02)00468-9","article-title":"The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2","volume":"9","author":"Zhang","year":"2002","journal-title":"Mol Cell"},{"issue":"6","key":"2025042211214097700_bib63","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/emboj\/cdg120","article-title":"Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1","volume":"22","author":"Yoon","year":"2003","journal-title":"EMBO J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/2006\/2370015\/blooda_adv-2024-015769-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/2006\/2370015\/blooda_adv-2024-015769-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T15:21:56Z","timestamp":1745335316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/2006\/535781\/Targeting-the-DNA-damage-response-through-TBL1X-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015769","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}